138 related articles for article (PubMed ID: 27058566)
21. [Biologics and biosimilars].
Guðmundsson K
Laeknabladid; 2014 May; 100(5):267. PubMed ID: 24846948
[No Abstract] [Full Text] [Related]
22. [Biosimilars - Potential, risks and open questions].
Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
[No Abstract] [Full Text] [Related]
23. Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019.
Hussaini SMQ; Gupta A; Anderson KE; Ballreich JM; Nicholas LH; Alexander GC
JAMA Netw Open; 2022 Mar; 5(3):e221117. PubMed ID: 35254434
[TBL] [Abstract][Full Text] [Related]
24. Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases.
Schulze-Koops H
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv1-iv3. PubMed ID: 28903541
[No Abstract] [Full Text] [Related]
25. Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant.
Giaccone L; Brunello L; Londono JS; Scaldaferri M; Cerrano M; Redoglia V; Omedè P; Lia G; Massaia M; Ferrero D; Cavallo F; Bringhen S; Leone S; Cattel F; Francisci T; Tassi V; Evangelista A; Boccadoro M; Bruno B
Bone Marrow Transplant; 2022 Feb; 57(2):312-314. PubMed ID: 34848834
[No Abstract] [Full Text] [Related]
26. Zarxio--a filgrastim biosimilar.
Med Lett Drugs Ther; 2016 Mar; 58(1490):34-5. PubMed ID: 26963154
[No Abstract] [Full Text] [Related]
27. [Biosimilars: regulatory status for approval].
Herrero Ambrosio A
Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
[TBL] [Abstract][Full Text] [Related]
28. Are biosimilars for pemphigus safe?
Ho G; Sheriff T; Doria-Ruiz M; Loh Y; Murrell DF
Clin Exp Dermatol; 2021 Jul; 46(5):942-943. PubMed ID: 33577125
[No Abstract] [Full Text] [Related]
29. [Biosimilar filgrastim: from development to record].
García Alfonso P
Farm Hosp; 2010 Mar; 34 Suppl 1():19-24. PubMed ID: 20920854
[TBL] [Abstract][Full Text] [Related]
30. The use of biosimilar drugs in psoriasis: a position paper.
Carretero Hernández G; Puig L;
Actas Dermosifiliogr; 2015 May; 106(4):249-51. PubMed ID: 25712906
[No Abstract] [Full Text] [Related]
31. The role of biosimilar granulocyte colony stimulating factor (GCSF) Zarzio for progenitor cell mobilization and the treatment of therapy-induced neutropenia in adult hematopoietic stem cell transplantation.
Severson CC
Can Oncol Nurs J; 2015; 25(4):443-54. PubMed ID: 26897866
[TBL] [Abstract][Full Text] [Related]
32. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.
Rioufol C; Salles G
Expert Rev Anticancer Ther; 2015 May; 15(5):569-78. PubMed ID: 25818308
[TBL] [Abstract][Full Text] [Related]
33. Effective pharmaceutical regulation needs alignment with doctors.
Ebbers HC; Pieters T; Leufkens HG; Schellekens H
Drug Discov Today; 2012 Feb; 17(3-4):100-3. PubMed ID: 22001600
[TBL] [Abstract][Full Text] [Related]
34. Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network.
Marchesi F; Cerchiara E; Dessanti ML; Gumenyuk S; Franceschini L; Palombi F; Pisani F; Romano A; Spadea A; Pupo L; Annibali O; La Malfa A; Arcese W; Mengarelli A
Br J Haematol; 2015 Apr; 169(2):293-6. PubMed ID: 25371286
[No Abstract] [Full Text] [Related]
35. Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors.
Abraham I; Tharmarajah S; MacDonald K
Expert Opin Drug Saf; 2013 Mar; 12(2):235-46. PubMed ID: 23419039
[TBL] [Abstract][Full Text] [Related]
36. Pharmacovigilance and biosimilars: considerations, needs and challenges.
Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
[TBL] [Abstract][Full Text] [Related]
37. The European biosimilars market remains underdeveloped.
Prescrire Int; 2015 Mar; 24(158):82. PubMed ID: 25897465
[No Abstract] [Full Text] [Related]
38. Impact of biosimilars in psoriasis treatment.
Torres T; Filipe P; Selores M
Acta Med Port; 2013; 26(6):646-8. PubMed ID: 24388249
[No Abstract] [Full Text] [Related]
39. Low-molecular-weight heparin biosimilars: potential implications for clinical practice. Australian Low-Molecular-Weight Heparin Biosimilar Working Group (ALBW).
Nandurkar H; Chong B; Salem H; Gallus A; Ferro V; McKinnon R;
Intern Med J; 2014 May; 44(5):497-500. PubMed ID: 24816308
[TBL] [Abstract][Full Text] [Related]
40. A consistency approach for evaluation of biosimilar products.
Tsou HH; Chang WJ; Hwang WS; Lai YH
J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
